The increasing need for new and improved vaccines and the growing level of sophistication of their associated adjuvantation and delivery systems has major implications for the design, formulation, delivery, manufacturing and quality assessment of modern vaccines and immune interventions in general. Following the successful MVAF meetings held in Prague, Dublin and Cannes, the follow-up conference MVAF 2013 will offer an international forum for the discussion of all aspects of vaccine formulation and will focus on:
- Innovation in vaccine design and adjuvantation/delivery technologies
- Challenges to manufacturing and the administration of modern vaccines
- Compliances with quality standards and regulatory requirements
MVAF 2013 will then assess the impact of all of the above on the future development/design of vaccines and adjuvants.
MVAF 2013 will be of interest to researchers/contributors from academic programs, industrial, governmental and regulatory groups. Contributions to both the oral and poster programs are encouraged. Potential contributors attention is drawn to the Call For Abstracts on the reverse of this brochure.
Scientific Advisory Panel
Conference Chair:
Geert Vanden Bossche (UNIVAC LLC, Seattle, Washington, USA)
Martin Friede (WHO, Geneva, Switzerland)
Nathalie Garcon (GSK Biologicals, Belgium)
Adriana Baz Morelli (CSL Ltd, Melbourne, Australia)
Jean Haensler (Sanofi Pasteur, France)
Danuta Herzyk (Merck Research Laboratories, USA)
Manmohan Singh (Novartis Vaccines, Cambridge, Massachusetts, USA)
Jan-Willem van der Laan (Medicines Evaluation Board, Utrecht, The Netherlands)
Lakshmi Khandke (Pfizer Vaccine Research, Pearl River, New York, USA)
Bruce Weniger (Chiang Mai University, Chiang Mai, Thailand)
Rob Lambkin-Williams (Retroscreen Virology Ltd, London, UK)
Gwyn Davies (St. George’s Hospital, London, UK)
Matthew Downham (Medimmune, Liverpool, UK)
Greg Glenn (Novavax Inc., Rockville, Maryland, USA)
Alan Shaw (Vendantra Corporation, Cambridge, Massachusetts, USA)
Niranjan Sardesai (Inovio Pharmaceuticals, Blue Bell, Pennsylvania, USA)
Gary Ott (Dynavax Inc., San Diego, California, USA)
Heather Davis (Pfizer Vaccines Research, Ottawa, Canada)
Steve Reed (IDRI, Seattle, Washington, USA)
Nicolas Collin (University of Lausanne, Lausanne, Switzerland)
Stephane Ascarateil (SEPPIC, Paris, France)
Guro Gafvelin (Viscogel AB, Solna, Sweden)
Conference Scope/Topics
The following list of topics is not exhaustive but reflects the variety of subjects that this area of vaccine/adjuvant technology and development encompasses:
Innovative Vaccine Concepts and Designs
Molecular Approaches to Vaccine Design
Vaccine Immunology/Immunogenicity Studies
Vaccine Design & Formulation
Modelling Methods
Vaccine/Adjuvant Delivery Issues & Systems
Vaccine/Adjuvant Diversity – Live or Inactivated Virus/Recombinant Protein
Polysaccharide or Peptide (free versus conjugated)
Viral Vectors/DNA Vectors
VLPs & Nanoparticulate Vaccines
Administration Devices/Methods (oral/nasal/transcutaneous/needle-free)
Process & Manufacturing
Protein Stabilization/Virus Stablization/Vaccine Stabilization
Vaccine Preservation Issues – New/Novel Vaccine Preservatives
Vaccine Stability Monitoring Methods
Characterization and quality assessment in compliance with regulatory guidelines
Vaccine/Adjuvant Quality, Purity & Potency/Efficacy & Safety
Safety Evaluation Considerations
Assay Development Aspects
Toxicology Studies
Regulatory Guidelines – National/International for Adjuvanted Vaccines
